Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Technetium Tc 99m Sestamibi
Brand Name
Technetium Tc 99m Sestamibi
Generic Name
Technetium Tc 99m Sestamibi
Active Ingredient
Technetium Tc-99m SestamibiCategory
Radioactive Diagnostic Agent [EPC]
Variants
2
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Technetium Tc 99m Sestamibi, you must consult a qualified healthcare professional.
Detailed information about Technetium Tc 99m Sestamibi
Technetium Tc-99m Sestamibi is a radioactive diagnostic agent used in nuclear medicine to visualize blood flow to the heart and detect certain types of tumors.
The dosage of Technetium Tc-99m Sestamibi is measured in units of radioactivity called millicuries (mCi) or Megabecquerels (MBq). The specific dose depends on the type of scan being performed and the patient's body weight.
Technetium Tc-99m Sestamibi is not commonly used in children, and its safety and effectiveness in pediatric populations have not been extensively established by the FDA. However, when medically necessary, pediatric dosing is usually calculated based on the child's body weight or body surface area, often following the North American Consensus Guidelines for pediatric nuclear medicine. Healthcare providers will use the minimum amount of radiation necessary to achieve a clear image.
Because a portion of the drug is excreted through the kidneys, patients with severe renal impairment (kidney failure) may retain the radioactive tracer longer than usual. While specific dose reductions are not always required, the medical team may encourage extra hydration to help flush the kidneys.
Since the liver and gallbladder are major routes of elimination, patients with liver disease may show slower clearance of the drug. This can sometimes interfere with the quality of heart images because the 'glow' from the liver can overlap with the heart. Doctors may adjust the timing of the images to allow the liver to clear.
In clinical studies, no overall differences in safety or effectiveness were observed between elderly patients (65 and over) and younger patients. Dosage is generally the same, though doctors will consider the patient's overall kidney and heart function.
Technetium Tc-99m Sestamibi is administered only by trained professionals in a clinical setting.
Since this medication is administered by a healthcare provider for a scheduled appointment, a missed dose is unlikely. However, if you miss your appointment, the 'kit' prepared for you will lose its radioactivity and must be discarded. You will need to reschedule to receive a fresh dose.
An 'overdose' in the context of Technetium Tc-99m Sestamibi refers to receiving more radiation than intended. Because the drug is carefully measured by a nuclear pharmacist and verified by a technician before injection, this is extremely rare. In the event of an accidental over-administration, the primary treatment is 'forced diuresis'—drinking large amounts of fluids and frequent urination to help the body eliminate the radioactive material as quickly as possible.
> Important: Follow your healthcare provider's dosing and preparation instructions exactly. Do not adjust your medications or diet before the test without medical guidance.
Technetium Tc-99m Sestamibi is generally very well tolerated, and most patients experience no side effects at all. However, some common experiences reported during or immediately after the injection include:
These side effects are less frequent but have been documented in clinical trials and post-marketing surveillance:
Technetium Tc-99m Sestamibi is a radioactive substance. While the levels used are diagnostic and generally safe, safety protocols must be followed to protect the patient and others. Patients should be aware that they will be 'radioactive' for a short period (about 24–48 hours) after the injection. During this time, the body is emitting small amounts of gamma radiation and excreting the isotope through urine and feces.
No FDA black box warnings for Technetium Tc-99m Sestamibi. It has a long-standing safety profile since its introduction in the early 1990s.
There are no drugs that are strictly 'contraindicated' with Technetium Tc-99m Sestamibi itself in terms of chemical toxicity. However, certain drugs are contraindicated with the stress agents (like Adenosine, Regadenoson, or Dipyridamole) often used alongside Sestamibi:
Technetium Tc-99m Sestamibi has very few absolute contraindications because it is used in small, one-time doses for critical diagnostics. However, the following apply:
These are conditions where the doctor will carefully weigh the risks versus the benefits:
Technetium Tc-99m Sestamibi is classified by the FDA as Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the drug can cause fetal harm when administered to a pregnant woman.
Ionizing radiation is known to be potentially harmful to a developing fetus, especially during the first trimester (organogenesis). If a Sestamibi scan is being considered for a pregnant woman, healthcare providers will usually look for alternative tests that do not involve radiation (such as an Ultrasound or an MRI without certain contrasts). If the scan is vital for the mother's survival (e.g., suspected acute heart attack), the lowest possible dose will be used.
Technetium Tc-99m Sestamibi is excreted in breast milk. According to the Nuclear Regulatory Commission (NRC) and various medical societies, breastfeeding should be suspended for a period of time following the injection. A 24-hour interruption is typically sufficient for the radioactivity to decay to a level that is safe for the infant. During this time, the mother should express and discard her milk.
Technetium Tc-99m Sestamibi is a lipophilic, cationic, organometallic complex. Its molecular mechanism for myocardial uptake involves passive diffusion across the plasma and mitochondrial membranes. Because of its positive charge and fat-solubility, it is drawn toward the negative electrical potential of the mitochondrial matrix.
Once inside the mitochondria, the sestamibi molecule remains trapped. It does not undergo significant 'washout' (leaving the cell) for several hours. This 'fixed' distribution allows clinicians to take 'snapshots' of the blood flow as it was at the exact moment of injection, even if the actual imaging happens an hour later.
Technetium Tc-99m Sestamibi has no known pharmacological effect at the doses used for imaging. It does not change heart rate, blood pressure, or cardiac output. Its only 'action' is the emission of 140 keV gamma photons, which are ideal for detection by standard gamma cameras used in hospitals.
| Parameter | Value |
Common questions about Technetium Tc 99m Sestamibi
Technetium Tc-99m Sestamibi is primarily used for myocardial perfusion imaging, which allows doctors to see how well blood is flowing to your heart muscle at rest and during stress. It is also used in a procedure called scintimammography to help find breast cancer in women who have had abnormal mammograms or have very dense breast tissue. Additionally, it is the gold standard for locating overactive parathyroid glands in patients with hyperparathyroidism. Because it is radioactive, it allows a gamma camera to create detailed 3D images of these internal organs. It is a diagnostic tool only and is not used to treat any medical conditions.
The most common side effect is a brief metallic or bitter taste in the mouth immediately following the injection, occurring in about 2-5% of patients. Some people may also experience a temporary feeling of warmth or flushing in the face, a mild headache, or slight nausea. Because the dose of the chemical is so small, true 'drug' side effects are rare; many symptoms patients feel are actually related to the stress test (exercise or stress-inducing medication) rather than the Sestamibi itself. Serious allergic reactions are extremely rare but are always monitored for by the medical staff. Most patients complete the procedure without any discomfort whatsoever.
You should generally avoid alcohol for at least 24 hours before your Technetium Tc-99m Sestamibi scan. While alcohol does not have a dangerous chemical reaction with the tracer, it can significantly alter your heart rate and blood pressure, which can make the results of a heart stress test difficult to interpret. After the scan is finished and the medical team has cleared you, there is no specific contraindication to drinking alcohol. However, it is always best to stay well-hydrated with water first to help flush the radioactive tracer out of your system. Always consult your cardiologist for their specific pre-test instructions.
Technetium Tc-99m Sestamibi is generally avoided during pregnancy because it involves exposure to ionizing radiation, which can potentially affect the developing fetus. It is classified as FDA Pregnancy Category C, meaning it should only be used if the potential benefit to the mother clearly outweighs the risk to the unborn baby. If you are pregnant or think you might be, you must inform your doctor before the procedure so they can consider alternative tests like an ultrasound. In non-emergency situations, the test is usually postponed until after delivery. If the test is absolutely necessary, the medical team will use the lowest dose possible to minimize fetal exposure.
Technetium Tc-99m Sestamibi begins to work immediately upon injection as it travels through your bloodstream to your heart or other target organs. However, the 'imaging window' usually begins 30 to 60 minutes after the injection. This delay is necessary to allow the tracer to clear from your blood and for 'background' radioactivity in the liver and lungs to decrease, which results in a much clearer picture of the heart. The entire procedure, including the stress test and the imaging time, usually takes between 2 and 4 hours. The radioactivity itself will remain in your body for about 2 days before it completely decays and is excreted.
Technetium Tc-99m Sestamibi is not a medication that you take on a regular basis, so there is no 'stopping' it. It is a one-time diagnostic injection given by a healthcare professional during a specific medical appointment. Once the injection is given, the body naturally eliminates it through urine and feces over the next 24 to 48 hours. There are no withdrawal symptoms or long-term dependencies associated with this agent. If you have concerns about the radiation remaining in your body, drinking plenty of fluids after the test is the best way to speed up the elimination process. You do not need to take any special actions to 'stop' the drug's effects.
Because Technetium Tc-99m Sestamibi is administered only by healthcare professionals in a hospital or clinic setting, you cannot 'miss a dose' in the traditional sense. If you miss your scheduled appointment for the scan, the radioactive dose prepared specifically for you will 'decay' and become useless within a few hours. You will need to call your imaging center to reschedule the appointment so they can order a fresh dose of the radiopharmaceutical. There are no health consequences to missing the dose other than the delay in getting your diagnostic results. Be sure to follow all pre-appointment instructions again for your rescheduled time.
No, Technetium Tc-99m Sestamibi does not cause weight gain. It is a single-dose diagnostic agent that contains an extremely minute amount of the actual sestamibi chemical—far too little to affect your metabolism, appetite, or fat storage. Any weight changes you may be experiencing are likely due to other factors, such as underlying heart conditions, other medications you may be taking (like certain beta-blockers), or changes in your exercise routine. If you are concerned about sudden weight gain, you should discuss this with your primary care doctor or cardiologist, as it can sometimes be a sign of worsening heart failure. This drug is cleared from your system entirely within a couple of days.
While Technetium Tc-99m Sestamibi doesn't have dangerous chemical reactions with most drugs, many medications can interfere with the *accuracy* of the scan. For example, beta-blockers and caffeine can prevent your heart from reaching the necessary stress level, leading to an incorrect 'normal' result. You must provide your doctor with a full list of your medications, especially heart, blood pressure, and asthma drugs. Your doctor will tell you which ones to stop taking and for how long (usually 24–48 hours) before the test. Never stop taking your prescribed heart medications without first consulting the doctor who ordered the Sestamibi scan.
Yes, Technetium Tc-99m Sestamibi is available as a generic radiopharmaceutical. It was originally marketed under the brand name Cardiolite. Today, several different manufacturers produce 'kits' for the preparation of the injection that are functionally identical to the original brand. In a hospital setting, the nuclear pharmacy will prepare the dose using whichever kit they have in stock. Whether you receive the brand name or the generic version, the diagnostic accuracy and the radiation dose you receive will be the same. The cost of the drug is usually bundled into the overall cost of the nuclear medicine procedure.
Other drugs with the same active ingredient (Technetium Tc-99m Sestamibi)
While extremely rare, serious reactions can occur. Because the drug is administered in a medical facility, staff are prepared to handle these emergencies.
> Warning: Stop the procedure and alert your medical team immediately if you experience any of the following:
Technetium Tc-99m Sestamibi is a single-use diagnostic agent, so it does not have 'long-term' side effects in the way daily medications (like blood pressure pills) do. The primary long-term consideration is the radiation risk.
Exposure to ionizing radiation carries a theoretical risk of inducing cancer many years later. However, the dose of radiation from a Sestamibi scan is relatively low—roughly equivalent to the amount of natural background radiation a person receives from the environment over 2 to 5 years. For most patients, the clinical benefit of accurately diagnosing a heart condition far outweighs the small theoretical risk of future cancer.
As of 2026, there are no FDA Black Box Warnings for Technetium Tc-99m Sestamibi. It is considered a safe and standard diagnostic tool when used according to established protocols.
Report any unusual symptoms or persistent side effects to your healthcare provider. Even if a symptom seems minor, it is important for the medical team to document it for your safety and for national safety monitoring databases.
There are no long-term lab tests required for Technetium Tc-99m Sestamibi because it is a one-time diagnostic event. However, during the procedure:
Technetium Tc-99m Sestamibi itself does not typically cause drowsiness or impairment. However, if you are given a sedative for the imaging (rare) or if you feel dizzy following a physical stress test (treadmill), you should not drive until you feel fully recovered. Most patients can drive themselves home after the procedure.
There are no known direct interactions between alcohol and Technetium Tc-99m Sestamibi. However, alcohol can affect heart rate and blood pressure, which may interfere with the results of a myocardial perfusion scan. It is generally recommended to avoid alcohol for 24 hours before the test.
As this is a single-dose diagnostic agent, there is no 'discontinuation' or 'tapering' process. Once the scan is complete and the radioactivity has decayed (within about 2 days), the drug is gone from your system.
> Important: Discuss all your medical conditions, especially any history of asthma, heart rhythm problems, or allergies, with your healthcare provider before starting Technetium Tc-99m Sestamibi.
Technetium Tc-99m Sestamibi does not typically interfere with standard blood chemistry or hematology tests. However, because the patient is radioactive, their blood or urine samples may trigger radiation alarms in highly sensitive laboratory equipment for about 24 hours after the procedure.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for heart rhythm, blood pressure, or asthma.
There is no known cross-sensitivity between Technetium Tc-99m Sestamibi and iodine-based contrast dyes (used in CT scans). If you are allergic to 'iodine' or 'shellfish,' you can still safely receive a Sestamibi scan, as it does not contain iodine.
> Important: Your healthcare provider will evaluate your complete medical history, including any recent radiation exposure, before prescribing Technetium Tc-99m Sestamibi.
Safety and effectiveness in children below the age of 18 have not been established by large-scale clinical trials. However, nuclear medicine specialists do use Sestamibi in children for specific indications, such as evaluating heart blood flow in congenital heart disease or identifying parathyroid issues. Dosing is strictly adjusted based on the child's weight to minimize radiation exposure.
Clinical studies have included a large number of subjects aged 65 and over. No specific differences in the safety profile or diagnostic accuracy were noted compared to younger adults. However, elderly patients are more likely to have reduced renal function. Since the drug is partially cleared by the kidneys, the medical team will ensure the patient is well-hydrated to facilitate the elimination of the tracer.
In patients with kidney disease or renal failure, the excretion of Technetium Tc-99m Sestamibi is delayed. This results in a slightly higher 'radiation absorbed dose' to the body because the radioactive material stays in the blood and tissues longer. No specific dose adjustment is usually required for the scan quality, but the patient should be encouraged to hydrate aggressively post-procedure.
Liver disease can significantly alter the 'biodistribution' of Sestamibi. Normally, the liver clears the drug and sends it into the bile and intestines. In patients with liver impairment, the drug may stay in the liver longer, creating a 'bright' spot that can overlap with the heart on the images. Technicians may wait longer (90–120 minutes) before taking pictures to allow for better liver clearance.
> Important: Special populations require individualized medical assessment to ensure the diagnostic benefits of the scan outweigh the radiation risks.
|---|---|
| Bioavailability | 100% (Intravenous) |
| Protein Binding | Low (primarily circulates free) |
| Physical Half-life | 6.02 Hours (Radioactive decay) |
| Biological Half-life | ~7 hours (Heart), ~30 mins (Blood) |
| Tmax | Immediate (post-injection) |
| Metabolism | Minimal (Physical decay only) |
| Excretion | Renal 27%, Fecal 33% (within 48h) |
Technetium Tc-99m Sestamibi is classified as a Radioactive Diagnostic Agent. It is part of the 'Technetium-99m labeled compounds' group. Related agents include Technetium Tc-99m Tetrofosmin (Myoview), which works via a similar mitochondrial mechanism, and Thallium-201, an older potassium-analog tracer that was the standard before Sestamibi was developed.